Theratechnologies (TSE:TH) Sets New 1-Year High - Here's What Happened

Key Points

• Theratechnologies Inc. shares reached a new 52-week high of C$4.34, indicating recent positive performance in the stock market.
• Analysts at Jones Trading downgraded Theratechnologies from a "strong-buy" rating to a "hold" rating, suggesting a more cautious outlook for investors.
• The company, which focuses on specialized pharmaceuticals for HIV patients, has two approved products: EGRIFTA and Trogarzo.
• Theratechnologies holds a market capitalization of C$138.47 million, with significant financial ratios including a P/E ratio of -49.13.

Theratechnologies Inc. (TSE:TH - Get Free Report) shares reached a new 52-week high on Friday . The stock traded as high as C$4.34 and last traded at C$4.34, with a volume of 36723 shares changing hands. The stock had previously closed at C$4.29.

Wall Street Analysts Forecast Growth

Separately, Jones Trading lowered shares of Theratechnologies from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 3rd.

Theratechnologies Price Performance

The company has a debt-to-equity ratio of -293.92, a current ratio of 1.08 and a quick ratio of 0.64. The firm has a fifty day moving average of C$3.73 and a two-hundred day moving average of C$3.05. The stock has a market capitalization of C$138.47 million, a P/E ratio of -49.13, a P/E/G ratio of -8.50 and a beta of 1.73.

About Theratechnologies

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.